---
title: "VKTX: VK2735 showed durable weight loss on less-frequent dosing; Phase 3 readouts lie ahead"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305922449.md"
description: "VK2735 maintenance data showed substantial weight loss retained with every-other-week or monthly dosing, while Phase 3 readouts are expected in 2H27 for injectable and 2028 for oral treatment. VK3019 and other metabolic programs are advancing.Original document: Viking Therapeutics, Inc. [VKTX] Slides Release — Nov. 18 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-11-18T06:18:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305922449.md)
  - [en](https://longbridge.com/en/news/305922449.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305922449.md)
generator: "portal-rs"
---

# VKTX: VK2735 showed durable weight loss on less-frequent dosing; Phase 3 readouts lie ahead

VK2735 maintenance data showed substantial weight loss retained with every-other-week or monthly dosing, while Phase 3 readouts are expected in 2H27 for injectable and 2028 for oral treatment. VK3019 and other metabolic programs are advancing.

Original document: Viking Therapeutics, Inc. \[VKTX\] Slides Release — Nov. 18 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [VKTX.US](https://longbridge.com/en/quote/VKTX.US.md)

## Related News & Research

- [Viking Therapeutics (VKTX) Could Be 77% Undervalued As VK2735 Obesity Data Draws Focus](https://longbridge.com/en/news/305696719.md)
- [Viking Therapeutics' VK2735 improves BMI category in 74% of patients in 13-week Phase 2 trial](https://longbridge.com/en/news/305578038.md)
- [Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026 | VKTX Stock News](https://longbridge.com/en/news/305578185.md)
- [Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028](https://longbridge.com/en/news/305443895.md)
- [Obesity Trial Data Might Change The Case For Investing In Viking Therapeutics Stock](https://longbridge.com/en/news/305137228.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**